Search results
Showing 31 to 45 of 729 results for innovative
In development Reference number: GID-TA11230 Expected publication date: 07 May 2026
Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Access free webinars and paid-for masterclasses.
Our projects and partnerships help us anticipate and adapt to policy developments, including changes in health and social care delivery.
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults.
Evidence-based recommendations on Synergo for non-muscle-invasive bladder cancer.
This quality standard covers recognising, assessing and managing coeliac disease in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS134Show all sections
Sections for QS134
- Quality statements
- Quality statement 1: Serological testing for coeliac disease
- Quality statement 2: Referral to a specialist
- Quality statement 3: Endoscopic intestinal biopsy
- Quality statement 4: Advice about a gluten-free diet
- Quality statement 5: Annual review
- Update information
- About this quality standard
We assess the value of digital health technologies that offer the greatest potential to improve health and wellbeing.
New hope for people with breathing condition, COPD, as NICE approves innovative treatment Breakthrough therapy reduces flare-ups by...
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults when systemically administered immunotherapies are not suitable.
Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)
Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.
Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer in adults.
Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.
Evidence-based recommendations on ceritinib (Zykadia) for treating advanced anaplastic lymphoma kinase positive non-small-cell lung cancer in adults who have had crizotinib.
Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.